Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Ruxolitinib for Premalignant Breast Disease
NCT02928978 · View on ClinicalTrials.gov ↗
Study Summary
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Conditions Studied
Interventions
- DRUG Ruxolitinib
- DRUG Placebo (for Ruxolitinib)
Study Locations (8)
Texas
- University of Texas MD Anderson Cancer Center — Houston
- Harris Health System - Smith Clinic — Houston
- O'Quinn Medical Tower - McNair Campus; Dan L Duncan Comprehensive Cancer Center — Houston
Alabama
- University of Alabama at Birmingham — Birmingham
Indiana
- Indiana University Melvin and Bren Simon Cancer Center — Indianapolis
New York
- Montefiore Medical Center — The Bronx
North Carolina
- University of North Carolina at Chapel Hill — Chapel Hill
Tennessee
- Vanderbilt-Ingram Cancer Center — Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-05-13 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02928978
The ClinicalTrials.gov registry entry for NCT02928978 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Julie Nangia, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 4 conditions, with Ductal Carcinoma In Situ appearing as the primary indexed condition, and to 2 interventions — of which Ruxolitinib is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT02928978 reports 8 study locations spanning 6 distinct geographic areas — top geographies include Texas, Alabama, Indiana. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT02928978 about?
NCT02928978 is a clinical study titled "Ruxolitinib for Premalignant Breast Disease". This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitini...
What is the current status of trial NCT02928978?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2018-05-13. Estimated completion is 2026-06.
What conditions does trial NCT02928978 study?
This clinical trial studies the following conditions: Ductal Carcinoma In Situ, Atypical Ductal Hyperplasia, Atypical Lobular Hyperplasia, Lobular Carcinoma In Situ. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT02928978?
The interventions under investigation include: Ruxolitinib (DRUG), Placebo (for Ruxolitinib) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT02928978?
This trial is sponsored by Julie Nangia, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT02928978 being conducted?
This trial has 8 study locations across Alabama, Indiana, New York, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.